4、为尊重中小投资者利益，提高中小投资者对本次股东大会决议事项的参 与度，本次股东大会对审议影响中小投资者利益的重大事项进行单独计票。中小 投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的其他股东。 一、会议召开和出席情况 （一）会议召开情况 证券代码：300451 证券简称：创业慧康 公告编号：2024-025 创业慧康科技股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无新增、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开； 1、召开时间： （1）现场会议日期和时间：2024 年 5 月 16 日（星期四）下午 14:30 （2）网络投票日期和时间：2024 年 5 月 16 日。其中，通过深圳证券交易 所交易系统进行网络投票的具体时间为：2024 年 5 月 16 日 9:15-9:25、9:30-11:30， 13:00-15:00。通过深圳证券交易所互联网投票 ...

一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司第八届董事会 证券代码：300451 证券简称：创业慧康 公告编号：2024-024 创业慧康科技股份有限公司 关于召开2023年年度股东大会的提示性公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2024 年 4 月 13 日在巨 潮资讯网披露了《关于召开 2023 年年度股东大会的通知》。本次股东大会将采 用现场表决与网络投票相结合的方式进行，为充分保障全体股东行使表决权，切 实保护广大投资者合法权益，现将有关事项再次通知如下： 5、会议召开方式：本次股东大会采取现场投票与网络投票相结合方式。 （1）现场投票：股东本人出席现场会议或者通过授权委托书（见附件一） 委托他人出席现场会议； 3、会议召开的合法、合规性 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络投票平台，股东可以在本公告公 布的网络投票时间内通过上述系统行使表决 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the stock price compared to the benchmark index within the next 6 to 12 months [5]. Core Views - The company's medical IT business is experiencing stable growth, with new products and services accelerating their implementation [1]. - The revenue for 2023 is projected at 1,616 million, with a growth rate of 6% year-over-year, while the net profit is expected to be 37 million, reflecting a decline of 14% year-over-year [8]. - The company has secured significant contracts in the healthcare sector, with a notable increase in revenue from its medical IT services, which accounted for 91.56% of total revenue [8]. Financial Summary - Revenue Forecast: - 2023: 1,616 million - 2024E: 1,944 million (20% growth) - 2025E: 2,314 million (19% growth) - 2026E: 2,761 million (19% growth) [4] - Net Profit Forecast: - 2023: 37 million - 2024E: 249 million (578% growth) - 2025E: 340 million (37% growth) - 2026E: 470 million (38% growth) [4] - Earnings Per Share (EPS): - 2023: 0.02 - 2024E: 0.16 - 2025E: 0.22 - 2026E: 0.30 [4] - Cash Flow: - Operating cash flow for 2023 is projected at 158 million, increasing to 459 million by 2026 [4]. Business Development - The company has successfully launched new products in the Internet of Things and smart healthcare sectors, with significant contracts signed for hospital management systems [8]. - The company has integrated its services with major partners like Philips, enhancing its product offerings and market reach [8]. - The customer base has been optimized, with a notable increase in the number of registered healthcare professionals and institutions utilizing the company's platforms [8].

Investment Rating - The report maintains a "Buy" rating for the company, with a reasonable value of 4.89 CNY per share based on a projected PE ratio of 33 times for 2024 [4][30]. Core Views - The company's Q1 2024 performance aligns with recovery expectations, achieving revenue of 380 million CNY, a year-on-year increase of 7.8%, and a net profit attributable to shareholders of 12.36 million CNY, up 19.0% year-on-year [1][30]. - The Hi-HIS product is set to enter a full promotion phase, with significant implementation across over 40 hospitals in 2023, including more than half being tertiary hospitals [1][30]. - Collaboration with Philips continues to advance, with the launch of the CareSync integrated smart hospital information system, enhancing the digital transformation of hospitals [1][30]. Financial Summary - Revenue projections for 2024-2026 are 1.89 billion CNY, 2.20 billion CNY, and 2.51 billion CNY, respectively, with net profits expected to be 230 million CNY, 366 million CNY, and 473 million CNY [2][30]. - The company’s EPS is forecasted to be 0.15 CNY, 0.24 CNY, and 0.31 CNY for 2024, 2025, and 2026, respectively [2][30]. - The EBITDA for the same period is projected to be 304 million CNY, 456 million CNY, and 565 million CNY [2][30].

来源：公司年报、国金证券研究所 创业慧康 (300451.SZ) 业绩简评 24Q1 公司实现毛利率 51.61%，与上年同期基本持平。三费同比 增长 1.53%，其中管理费用较上年同期下降 8.2%，销售费用同比 微增 1.12%，研发费用同比增长 12.50%，主要系公司在 AI、低 代码等领域加大投入所致。 公司 Hi-HIS 项目推进顺利，23 年新签订单 22 个，并于近期与苏 州市立医院集团正式签署战略合作协议，共同打造"市立智慧医 疗生态圈"。公司与飞利浦合作研发的飞悦康 CareSync 已正式亮 相，将借助飞利浦拓展增量客户，并在医疗设备销售领域深入合 作。 2024 年 4 月 25 日，公司发布 24 年一季报，Q1 实现营收 3.75 亿元，同比增长 7.76%；实现归母净利润 0.12 亿元，同比增长 19.03%；Q1 扣非归母净利润为 0.10 亿元，同比增长 51.52%， 主要系营收增长、成本费用同比增长 5.0%低于营收增速。 盈利预测、估值与评级 我们预计 2024-2026 年公司实现营业收入 20.23/25.55/32.41 亿 元 ，同比增长 25.20%/26. ...

1、本次计提信用减值准备和资产减值准备的原因 证券代码：300451 证券简称：创业慧康 公告编号: 2024-023 创业慧康科技股份有限公司 关于 2024 年第一季度计提信用减值准备和资产减值准备 的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2024 年第一季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 | 项 目 | 确定组合的依据 | 计量预期信用损失的方法 | | --- | --- | --- | | 其他应收款——应收利息组合 其他应收款——应收股利组合 | 款项性质 | 参考历史信用损失经验， 结合当前状况以及对未来 经济状况的预测，通过违 | | | | 约风险敞口和未来12个月 | | 其他应收款——应收合并范围内 | | 内或整个存续期预期信用 | | 关联方组合 | | 损失率，计算预期信用损 ...

Revenue and Profit Growth - Revenue for Q1 2024 increased by 7.76% to 375,491,442.27 yuan compared to the same period last year[5] - Net profit attributable to shareholders rose by 19.03% to 12,359,662.56 yuan year-over-year[5] - Net profit after deducting non-recurring gains and losses surged by 51.52% to 9,658,288.80 yuan[5] - Total operating revenue for the quarter was 375,491,442.27 yuan, an increase from 348,436,396.10 yuan in the same period last year[49] - Net profit attributable to the parent company's owners was 12,359,662.56 yuan, compared to 10,383,267.51 yuan in the previous year[50] R&D and Development Expenditure - Development expenditure increased by 199.14% due to capitalized R&D investments[7] - Development expenditure increased significantly to 51,527,042.13 yuan from 17,224,899.15 yuan, indicating increased investment in R&D[45] Taxes and Other Income - Taxes and surcharges grew by 71.24% due to increased revenue and reduced VAT input tax[7] - Other income decreased by 75.84% due to reduced VAT refunds[8] - Tax refunds received declined by 79.12% year-over-year[23] Cash Flow and Financial Activities - Cash received from investment recovery dropped by 41.32% compared to the previous year[9] - Net cash flow from operating activities was -200,644,939.83, a decrease of 7.52% compared to the previous year[36] - Net cash flow from investing activities was -84,283,588.85, an improvement of 22.16% compared to the previous year[36] - Net cash flow from financing activities was -67,352.65, a significant improvement from -100,000,000.00 in the previous year[36] - Cash received from other investment activities decreased by 42.11% year-over-year, mainly due to reduced purchase and redemption of wealth management products[39] - Cash paid for debt repayment decreased by 100,000,000 year-over-year, mainly due to no bank loan repayment occurring in the current period[39] - Operating cash inflow was 270,290,454.38 yuan, compared to 259,880,225.83 yuan in the same period last year[50] Financial Expenses and Income - Financial expenses decreased by 5,619,400 yuan due to increased interest income[22] - Financial expenses showed a net income of 10,848,488.25 yuan, primarily due to interest income of 11,134,456.08 yuan[49] Investment and Fair Value Changes - Investment income decreased by 161.80% year-over-year, mainly due to reduced investment income from associates[39] - Fair value change income increased by 1,369,100 year-over-year, mainly due to the increase in fair value of other non-current financial assets[39] - Asset impairment loss increased by 2,075,200 year-over-year, mainly due to increased provision for contract asset impairment[39] Assets and Liabilities - Total assets decreased from 5,790,350,720.78 to 5,663,734,821.97, a decline of 2.19%[31] - Total liabilities decreased from 1,126,467,178.33 to 978,024,354.93, a decline of 13.16%[31] - Total assets at the end of the quarter were 5,663,734,821.97 yuan, a decrease from 5,790,350,720.78 yuan at the beginning of the period[49] - Cash and cash equivalents decreased to 806,579,209.32 yuan from 1,094,386,640.73 yuan at the beginning of the period[45] - Accounts receivable increased to 1,708,390,778.27 yuan from 1,579,674,434.61 yuan at the beginning of the period[45] - Total equity attributable to the parent company's owners was 4,625,908,290.50 yuan, slightly up from 4,605,980,419.11 yuan at the beginning of the period[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 37,506[41] - Ge Hang holds 14.24% of the shares, totaling 220,519,182 shares, with 165,389,386 shares under restricted conditions[41] - Philips (China) Investment Co., Ltd. holds 10.01% of the shares, totaling 155,003,087 shares, all of which are unrestricted[41] - Zhejiang Xinsu Technology Co., Ltd. holds 2.50% of the shares, totaling 38,743,590 shares, all of which are unrestricted[41] - China Bank - Huabao CSI Medical ETF holds 2.33% of the shares, totaling 36,018,329 shares, all of which are unrestricted[41] - Hong Kong Securities Clearing Company Ltd. holds 1.93% of the shares, totaling 29,822,830 shares, all of which are unrestricted[41] - Zhang Lüzheng holds 1.88% of the shares, totaling 29,173,538 shares, with 21,880,153 shares under restricted conditions[41] - China Industrial and Commercial Bank - Caitong Asset Management Value Growth Mixed Fund holds 1.48% of the shares, totaling 22,877,306 shares, all of which are unrestricted[41] - Basic Pension Insurance Fund 1205 Portfolio holds 1.00% of the shares, totaling 15,425,640 shares, all of which are unrestricted[41] - China Construction Bank - China Merchants Flexible Allocation Mixed Fund holds 0.97% of the shares, totaling 15,000,000 shares, all of which are unrestricted[41] Earnings Per Share and Accounting Standards - Basic earnings per share remained stable at 0.01 yuan, consistent with the previous year[50] - The company will implement new accounting standards starting from 2024, which will affect the initial financial statements for the year[52] - The audit report has been reviewed and approved by the Board of Directors of Chuangye Huikang Technology Co., Ltd[52] Accounts Receivable and Financing - Accounts receivable financing increased by 69.95% due to higher bank acceptance bills[21]

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 4.50 yuan [7][26]. Core Views - The company achieved a revenue of 1.616 billion yuan in 2023, representing a year-on-year growth of 5.81%. However, the net profit attributable to the parent company decreased by 13.93% to 37 million yuan, and the net profit after deducting non-recurring items fell by 27.44% to 34 million yuan [7][10]. - The Hi-HIS system is entering a new phase of nationwide promotion, with a significant increase in order amounts year-on-year. The company signed 22 Hi-HIS-related orders in 2023, with a substantial increase in order value [7][10]. - The collaboration with Philips is expected to create a new growth engine for the business, focusing on the integration of medical information products and Philips' medical devices [7][10]. Financial Summary - The company forecasts revenue growth from 1.898 billion yuan in 2024 to 2.683 billion yuan in 2026, with corresponding net profits projected to rise from 161 million yuan to 309 million yuan during the same period [2][7]. - The earnings per share (EPS) is expected to increase from 0.10 yuan in 2024 to 0.20 yuan in 2026, with a price-to-earnings (P/E) ratio decreasing from 37 times to 19 times [2][7]. - The company is positioned in the first tier of domestic medical information software suppliers and is expected to benefit from supportive government policies in the healthcare information industry [7][10].

多方位巩固龙头优势，盈利能力有望修复 | --- | --- | --- | --- | --- | |-------------------------------------------------------|---------------|----------------|----------------|----------------| | | | | | | | [Table_MainProfit] 指标 / 年度 营业收入（百万元） | 2023A | 2024E | 2025E | 2026E | | 增长率 | 1615.87 5.81% | 1867.72 15.59% | 2220.93 18.91% | 2648.48 19.25% | | 归属母公司净利润（百万元） | 36.69 | 202.17 | 277.08 | 390.26 | | 增长率 | -13.95% | 451.05% | 37.05% | 40.84% | | 每股收益 EPS （元） | 0.02 | 0.13 | 0.18 | 0.25 | | 净资产收益率 ROE | 0.98% | 5.12% | 6 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on expected performance relative to market indices [23]. Core Insights - In 2023, the company achieved revenue of 1.616 billion yuan, a year-on-year increase of 5.81%, while the net profit attributable to shareholders decreased by 13.93% to 37 million yuan [2]. - The company has secured 29 software orders exceeding 10 million yuan each, totaling nearly 500 million yuan, indicating a robust demand in the healthcare information technology sector [2]. - The partnership with Philips is expected to enhance product offerings and drive growth, particularly in AI applications within healthcare [3][18]. Financial Performance Summary - Revenue for 2023 was 1.616 billion yuan, with a gross margin of 46.98%, down 2.41 percentage points year-on-year [2]. - The company forecasts revenues of 1.888 billion yuan, 2.249 billion yuan, and 2.642 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 16.84%, 19.11%, and 17.50% [3][19]. - The net profit is projected to rebound significantly, reaching 222 million yuan in 2024, reflecting a growth rate of 505.58% [3][19]. Operational Developments - The Hi-HIS system has been implemented in over 40 hospitals, with a significant portion being tertiary hospitals, showcasing the company's expanding footprint in the healthcare sector [9]. - The company has made necessary personnel preparations to handle the increasing order volume, although this has led to higher operational costs [2]. Market Position and Future Outlook - The strategic collaboration with Philips is anticipated to create synergies in product development and market reach, positioning the company favorably in the healthcare IT landscape [3][18]. - The report suggests maintaining attention on the company due to its focus on healthcare information technology and the expected recovery in industry demand [3].